股本结构
单位：万股
| 公告日期 | 2018-08-09 | 2018-08-09 | 2018-04-27 | 2018-05-02 | 2018-03-07 | 2018-03-07 |
|---|---|---|---|---|---|---|
| 证券总股本 | 3724.01 | 3714.73 | 3703.78 | 3693.36 | 3688.18 | 3654.18 |
| 普通股本 | 3724.01 | 3714.73 | 3703.78 | 3693.36 | 3688.18 | 3654.18 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2018-07-30 | 2018-06-30 | 2018-04-23 | 2018-03-31 | 2018-03-02 | 2017-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2018-08-09 | 3724.01 | 未披露 | 定期报告 | 2018-07-30 |
| 2018-08-09 | 3714.73 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-04-27 | 3703.78 | 未披露 | 定期报告 | 2018-04-23 |
| 2018-05-02 | 3693.36 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-07 | 3688.18 | 未披露 | 定期报告 | 2018-03-02 |
| 2018-03-07 | 3654.18 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of stock options
Vesting of restricted stock
|
2017-12-31 |
| 2017-12-22 | 3653.09 | 未披露 | 定期报告 | 2017-12-21 |
| 2017-11-01 | 3625.26 | 未披露 | 定期报告 | 2017-10-27 |
| 2017-11-01 | 3615.86 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-01 | 3602.17 | 未披露 | 定期报告 | 2017-07-28 |
| 2017-08-01 | 3593.88 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 3564.23 | 未披露 | 定期报告 | 2017-05-05 |
| 2017-04-28 | 3563.30 | 未披露 | 定期报告 | 2017-04-21 |
| 2017-05-09 | 3557.56 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-03 | 3541.85 | 未披露 | 定期报告 | 2017-02-24 |
| 2017-03-03 | 3528.10 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Exercise of stock options
Vesting of restricted stock
|
2016-12-31 |
| 2016-11-02 | 3505.86 | 未披露 | 定期报告 | 2016-10-28 |
| 2016-11-02 | 3499.62 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-03 | 3492.74 | 未披露 | 定期报告 | 2016-07-29 |
| 2016-08-03 | 3486.51 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-03 | 3460.26 | 未披露 | 定期报告 | 2016-04-29 |
| 2016-05-03 | 3459.26 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-01 | 3454.10 | 未披露 | 定期报告 | 2016-02-26 |
| 2016-03-01 | 3451.38 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Exercise of stock options
Vesting of restricted stock
Issuance of common stock from Roche transaction, net of issuance costs
|
2015-12-31 |
| 2015-11-03 | 3445.12 | 未披露 | 定期报告 | 2015-11-02 |
| 2015-11-03 | 3439.69 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-07 | 3438.26 | 未披露 | 定期报告 | 2015-08-03 |
| 2015-08-07 | 3428.14 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-11 | 3426.63 | 未披露 | 定期报告 | 2015-05-06 |
| 2015-04-30 | 3422.77 | 未披露 |
更多>>
On April 7, 2015, the transactions contemplated by the Transaction Agreement were consummated (the “Closing”). In connection with the Closing, Roche acquired 15,604,288 Shares for aggregate consideration of approximately $780.2 million (the “Tender Offer Shares”) and completed its primary investment in the Company of $250 million in cash to purchase 5,000,000 newly issued Shares at a price of $50.00 per Share.
|
2015-04-24 |
| 2015-05-11 | 2917.61 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-13 | 2913.20 | 未披露 | 定期报告 | 2015-03-09 |
| 2015-02-19 | 2855.74 | 未披露 | 定期报告 | 2015-02-11 |
| 2015-03-13 | 2822.40 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Exercise of stock options
Vesting of restricted stock
|
2014-12-31 |
| 2014-11-13 | 2831.09 | 未披露 | 定期报告 | 2014-11-07 |
| 2014-11-13 | 2809.58 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-13 | 2826.08 | 未披露 | 定期报告 | 2014-08-08 |
| 2014-08-13 | 2797.18 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-13 | 2819.22 | 未披露 | 定期报告 | 2014-05-07 |
| 2014-04-30 | 2811.91 | 未披露 | 定期报告 | 2014-04-21 |
| 2014-05-13 | 2779.47 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-20 | 2772.33 | 未披露 | 定期报告 | 2014-03-15 |
| 2014-03-07 | 2766.38 | 未披露 | 定期报告 | 2014-03-05 |
| 2014-03-07 | 2763.08 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Conversion of redeemable convertible preferred stock into common stock
Issuance of common stock from initial public offering, net of underwriters’ discounts and issuance costs
Issuance of common stock in exchange for services
Exercise of warrant for common stock
Exercise of stock options
Vesting of restricted stock
|
2013-12-31 |
| 2013-11-12 | 2813.82 | 未披露 | 定期报告 | 2013-11-06 |
| 2013-11-12 | 2733.64 | 未披露 |
更多>>
Upon closing of the IPO on September 30, 2013, all of the outstanding shares of the Company’s convertible preferred stock were converted into 17,128,024 shares of its common stock.
|
2013-09-30 |
| 2013-09-25 | 2717.23 | 未披露 |
更多>>
a 1-for-4 reverse split of our common stock effected on September 12, 2013;
the conversion of all of our outstanding 68,512,134 shares of preferred stock into 17,128,026 shares of common stock upon the closing of this offering;
the conversion of the warrant exercisable into 200,000 shares of preferred stock into a warrant exercisable for 50,000 shares of common stock;
|
2013-09-25 |
| 2013-09-25 | 415.54 | 未披露 |
更多>>
a 1-for-4 reverse split of our common stock effected on September 12, 2013
|
2013-09-13 |
| 2013-08-27 | 1661.21 | 未披露 | 定期报告 | 2013-07-31 |
| 2013-08-16 | 1276.13 | 6851.21 |
更多>>
from December 31, 2012 to June 30, 2013
Issuance costs related to Series B preferred stock offering (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
|
2013-06-30 |
| 2013-07-29 | 1179.59 | 6851.21 |
更多>>
from December 31, 2012 to March 31, 2013
Issuance costs related to Series B preferred stock offering (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
|
2013-03-31 |
from December 31, 2016 to December 31, 2017
Exercise of stock options
Vesting of restricted stock
from December 31, 2015 to December 31, 2016
Exercise of stock options
Vesting of restricted stock
From December 31, 2014 to December 31, 2015
Exercise of stock options
Vesting of restricted stock
Issuance of common stock from Roche transaction, net of issuance costs
On April 7, 2015, the transactions contemplated by the Transaction Agreement were consummated (the “Closing”). In connection with the Closing, Roche acquired 15,604,288 Shares for aggregate consideration of approximately $780.2 million (the “Tender Offer Shares”) and completed its primary investment in the Company of $250 million in cash to purchase 5,000,000 newly issued Shares at a price of $50.00 per Share.
from December 31, 2013 to December 31, 2014
Exercise of stock options
Vesting of restricted stock
from December 31, 2012 to December 31, 2013
Conversion of redeemable convertible preferred stock into common stock
Issuance of common stock from initial public offering, net of underwriters’ discounts and issuance costs
Issuance of common stock in exchange for services
Exercise of warrant for common stock
Exercise of stock options
Vesting of restricted stock
Upon closing of the IPO on September 30, 2013, all of the outstanding shares of the Company’s convertible preferred stock were converted into 17,128,024 shares of its common stock.
a 1-for-4 reverse split of our common stock effected on September 12, 2013;
the conversion of all of our outstanding 68,512,134 shares of preferred stock into 17,128,026 shares of common stock upon the closing of this offering;
the conversion of the warrant exercisable into 200,000 shares of preferred stock into a warrant exercisable for 50,000 shares of common stock;
a 1-for-4 reverse split of our common stock effected on September 12, 2013
from December 31, 2012 to June 30, 2013
Issuance costs related to Series B preferred stock offering (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
from December 31, 2012 to March 31, 2013
Issuance costs related to Series B preferred stock offering (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)